TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Fulcrum Therapeutics ( (FULC) ) just unveiled an announcement.
On December 6, 2025, Fulcrum Therapeutics announced positive initial results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir for sickle cell disease at the 67th American Society of Hematology Annual Meeting. The trial showed a significant increase in fetal hemoglobin levels, with 58% of patients achieving levels associated with reduced vaso-occlusive crises. Pociredir was well-tolerated with no serious adverse events, reinforcing its potential as a best-in-class treatment for sickle cell disease.
The most recent analyst rating on (FULC) stock is a Buy with a $23.00 price target. To see the full list of analyst forecasts on Fulcrum Therapeutics stock, see the FULC Stock Forecast page.
Spark’s Take on FULC Stock
According to Spark, TipRanks’ AI Analyst, FULC is a Neutral.
Fulcrum Therapeutics’ overall score is driven by strong technical indicators and positive earnings call sentiment, highlighting clinical progress and a solid financial position. However, challenges with profitability and valuation due to net losses and no dividend yield moderate the score.
To see Spark’s full report on FULC stock, click here.
More about Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases. Their lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease.
Average Trading Volume: 669,572
Technical Sentiment Signal: Strong Buy
Current Market Cap: $481.7M
For detailed information about FULC stock, go to TipRanks’ Stock Analysis page.